Skip to main content

Table 1 Clinical data of the multiple sclerosis patient cohort

From: Network alterations underlying anxiety symptoms in early multiple sclerosis

Demographic and clinical data

Multiple sclerosis patients (n = 92)

Sex (female/male)

62/30

  

Disease course at baseline (CIS/RRMS)

21/71

  

Mean age at baseline MRI (SD) [years]

34.4 ± 9.5

  

Mean age at disease onset (SD) [years]

32.5 ± 9.5

  

Mean disease duration (SD) [years]

1.9 ± 3.4

  

DMD (no/first line/second line)c

24/54/14

  

Mean follow-up (SD) [years]

2.4 ± 1.4

  

Mean EDSS score (SD)

1.2 ± 1.1

  

Mean HADS-A score (SD) after 2 years

5.5 ± 4.1

  

Volumetric analysis

Baseline

Follow-up

p value

Mean GM volume (SD) [ml]

632 ± 629

614 ± 607

0.001a

Mean TB volume (SD) [ml]

1441 ± 1411

1436 ± 1411

0.008a

Median T2 WM lesion volume (range) [ml]

1.5 (0.1–83.2)

2.0 (0.1–124.3)

0.001b

  1. Demographic and clinical data as well as brain volumetric measurements of early-stage multiple sclerosis patients at baseline MR scan and after follow-up
  2. CIS clinically isolated syndrome, RRMS relapsing–remitting multiple sclerosis, SD standard deviation, EDSS Expanded Disability Status Scale, GM grey matter, TB total brain, DMD disease-modifying drugs, HADS-A Hospital Anxiety and Depression Scale-Anxiety subscale
  3. ap values derived from paired t test
  4. bp values derived from Wilcoxon signed-rank test
  5. cFirst line: glatiramer acetate, interferon-beta, teriflunomide, dimethyl fumarate; second line: natalizumab, fingolimod, alemtuzumab